Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)

Published:2022-09-20 Issue:S2 Volume:97 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Aronson Julia H.¹,Skånland Sigrid S.²³,Roeker Lindsey E.¹,Thompson Meghan C.¹,Mato Anthony R.¹^ORCID

Affiliation:

1. CLL Program, Division of Hematological Oncology Memorial Sloan Kettering Cancer Center New York New York USA

2. Department of Cancer Immunology, Institute for Cancer Research Oslo University Hospital Oslo Norway

3. The K. G. Jebsen Centre for B Cell Malignancies, Institute for Clinical Medicine University of Oslo Oslo Norway

Funder

Norges Forskningsråd

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26682

Reference42 articles.

1. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

2. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

3. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

4. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

5. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08

2. Immunophenotyping with (phospho)protein profiling and fluorescent cell barcoding for single-cell signaling analysis and biomarker discovery;npj Precision Oncology;2024-05-20

3. Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review;Cancers;2024-03-26

4. Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia;OncoTargets and Therapy;2024-03

5. Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL);Genes;2023-12-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3